Drug Overview
Pfizer’s RSV preF vaccine is based on the prefusion form of the RSV fusion protein, aided by the discovery of the crystal structure of key viral proteins by the National Institutes of Health. It is currently in Phase I/II development in the US for the prevention of RSV infection in infants via maternal immunization, as well as in the elderly. The vaccine is designed to stimulate the production of serum anti-F immunoglobulin G in the mother, which can then be transferred to the fetus across the placenta and provide protection for the first six months of life when the risk of hospitalization is highest.
Analyst Outlook
Pfizer’s respiratory syncytial virus (RSV) subunit vaccine is based on the prefusion form of the RSV fusion (preF) protein. It is currently in Phase I/II development in the US for the prevention of RSV infection in infants via maternal immunization, as well as in the elderly. However, given that Pfizer has only initiated human trials in Q2 2018, it is likely to launch several seasons behind GlaxoSmithKline’s rival preF protein vaccine in the maternal sector. As such, RSV preF vaccine will need to display superior protection rather than just immunogenicity, or else be priced at a discount if it is to capture significant market share. For vaccination of the elderly, Pfizer’s vaccine is forecast to launch in the 2022/23 season, and will face fierce competition from Johnson & Johnson’s (Ad26.RSV.preF vaccine) and Novavax’s (RSV F vaccine) vaccines, both forecast to launch in the 2021/22 season, as well as Bavarian Nordic’s MVA-BN RSV vaccine, expected to launch in the 2022/23 season.
Pfizer’s RSV preF vaccine is based on the prefusion form of the RSV fusion protein, aided by the discovery of the crystal structure of key viral proteins by the National Institutes of Health. It is currently in Phase I/II development in the US for the prevention of RSV infection in infants via maternal immunization, as well as in the elderly. The vaccine is designed to stimulate the production of serum anti-F immunoglobulin G in the mother, which can then be transferred to the fetus across the placenta and provide protection for the first six months of life when the risk of hospitalization is highest.
Analyst Outlook
Pfizer’s respiratory syncytial virus (RSV) subunit vaccine is based on the prefusion form of the RSV fusion (preF) protein. It is currently in Phase I/II development in the US for the prevention of RSV infection in infants via maternal immunization, as well as in the elderly. However, given that Pfizer has only initiated human trials in Q2 2018, it is likely to launch several seasons behind GlaxoSmithKline’s rival preF protein vaccine in the maternal sector. As such, RSV preF vaccine will need to display superior protection rather than just immunogenicity, or else be priced at a discount if it is to capture significant market share. For vaccination of the elderly, Pfizer’s vaccine is forecast to launch in the 2022/23 season, and will face fierce competition from Johnson & Johnson’s (Ad26.RSV.preF vaccine) and Novavax’s (RSV F vaccine) vaccines, both forecast to launch in the 2021/22 season, as well as Bavarian Nordic’s MVA-BN RSV vaccine, expected to launch in the 2022/23 season.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
